Dr. Eric Smith is a leading figure in the field of bispecific antibodies with over 20 years of experience in the pharmaceutical industry. He received his Ph.D. in Microbiology and Immunology from Duke University in 1997, and followed that with a postdoctoral fellowship at NYU. He then joined Regeneron in 2002, initially focusing on the development of cytokine traps and related molecules. His expertise in protein engineering and immunology soon drew him towards the field of bispecific antibodies, molecules that can simultaneously bind to two distinct targets and offer unique therapeutic possibilities. Dr. Smith was a founding member of the bispecific antibody group at Regeneron in 2007 and he played a key role in establishing Regeneron’s bispecific platform, which is focused on engineering fully human bispecific antibodies with optimal efficacy and safety profiles. His work has resulted in numerous patents and peer-reviewed publications, as well as the generation of more than 10 therapeutic candidate molecules currently in clinical or late-stage pre-clinical development. Currently Dr. Smith is the Executive Director of Bispecifics at Regeneron with responsibility for the discovery and development of bispecific and other antibody-based therapeutics for a variety of important areas of unmet medical need. He is also active in the protein engineering community, presenting at and helping to organize national and international conferences on antibody engineering and bispecific antibodies.
You are here: / Eric Smith, Ph.D.